Animal Excretion Studies to Support Your Drug’s Development
An absorption, distribution, metabolism, and excretion (ADME) study package can be variable depending on a drug candidate’s chemical properties, but a standard in vivo package includes mass balance and biliary excretion studies to determine route and rate of elimination of a parent drug and its metabolites.
Regulatory agencies recommend conducting mass balance studies proactively, i.e., pre-IND, to gather appropriate data to inform study design and dosing considerations for first in-human (FIH) clinical trials. Armed with corroborative in vivo and in vitro data illuminating ADME characteristics of their drug compound, drug developers can move forward from preclinical to clinical development with confidence that they have the information they need to conduct safe, informed clinical trials.
In Vivo Excretion Studies We Offer
Other Excretion Route Capabilities
- Lymphatic Partition rate
- Excretion into milk
Our Approach to Preclinical Excretion Studies
We offer in vivo excretion studies using radiolabeled or unlabeled compound to accurately quantify drug-related material in excreta or bile of treated animals. Our team at the Drug Development Solutions Center in Tokai, Japan, has been working with radiolabeled pharmaceutical compounds and conducting in vivo ADME studies for more than 50 years and in addition to vast experience and training, they carry out all services at a sprawling state-of-the-art AAALAC-accredited facility with capacity to house hundreds of animals and meet strict quality and ethical standards of FDA, EMA, and PMDA regulations.
Working with the Drug Development Solutions Center
All RI-labeled compound shipping and handling are seamlessly managed by a designated study director or business development representative who will coordinate all communications throughout the process. Working with our team, clients can be confident they will get signature, unparalleled customer service and technical expertise from SEKISUI XenoTech and the Drug Development Solutions Center.
Our team of experts has built a strong reputation for quick response time and dedicated, experienced study directors handling each and every study, whether carried out in Kansas City or Tokai. By contracting a Drug Development Solutions Center study through SEKISUI XenoTech, we make it easy for North American and European clients to benefit from the years of experience our Tokai team has built. Read more in our blog about how we make it easy to work with the Drug Development Solutions Center for your in vivo nonclinical services.
Studies conducted at Drug Development Solutions Center also meet or exceed standards required by regulatory authorities, including FDA and EMA, just as with our Kansas City campus. While in the United States, there is no method by which an institution can claim certified compliance with Good Laboratory Practice (GLP) standards, the PMDA can grant certification following an inspection that approves a Japanese facility as GLP-compliant in specific practices. The Drug Development Solutions Center has this certification for all bioanalytical services, a critical component of many animal studies. The Center is also certified by AAALAC International for ethical use of animals in research so you can be sure services exceed quality standards required by the FDA upon IND or NDA submission.
Data from a rodent mass balance study is used with QWBA distribution data to provide critical exposure inputs for dosimetry calculations, which are required for planning radiolabeled mass balance studies in human absorption, metabolism, and excretion (hAME) studies– find out more about planning your next QWBA study with us.